JP7525903B2 - Ｃｘｃｒ４阻害剤の組成物ならびに調製および使用の方法 - Google Patents

Ｃｘｃｒ４阻害剤の組成物ならびに調製および使用の方法 Download PDF

Info

Publication number
JP7525903B2
JP7525903B2 JP2021510759A JP2021510759A JP7525903B2 JP 7525903 B2 JP7525903 B2 JP 7525903B2 JP 2021510759 A JP2021510759 A JP 2021510759A JP 2021510759 A JP2021510759 A JP 2021510759A JP 7525903 B2 JP7525903 B2 JP 7525903B2
Authority
JP
Japan
Prior art keywords
composition
pharma
acceptable salt
ceutically acceptable
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021510759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535146A5 (OSRAM
JP2021535146A (ja
Inventor
カレル マリー ジョゼフ ブランズ，
Original Assignee
エックス４ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エックス４ ファーマシューティカルズ， インコーポレイテッド filed Critical エックス４ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2021535146A publication Critical patent/JP2021535146A/ja
Publication of JP2021535146A5 publication Critical patent/JP2021535146A5/ja
Priority to JP2024111620A priority Critical patent/JP2024138443A/ja
Application granted granted Critical
Publication of JP7525903B2 publication Critical patent/JP7525903B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021510759A 2018-08-31 2019-08-30 Ｃｘｃｒ４阻害剤の組成物ならびに調製および使用の方法 Active JP7525903B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024111620A JP2024138443A (ja) 2018-08-31 2024-07-11 Ｃｘｃｒ４阻害剤の組成物ならびに調製および使用の方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862726010P 2018-08-31 2018-08-31
US62/726,010 2018-08-31
US16/215,963 US10548889B1 (en) 2018-08-31 2018-12-11 Compositions of CXCR4 inhibitors and methods of preparation and use
US16/215,963 2018-12-11
PCT/US2019/049065 WO2020047410A1 (en) 2018-08-31 2019-08-30 Compositions of cxcr4 inhibitors and methods of preparation and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024111620A Division JP2024138443A (ja) 2018-08-31 2024-07-11 Ｃｘｃｒ４阻害剤の組成物ならびに調製および使用の方法

Publications (3)

Publication Number Publication Date
JP2021535146A JP2021535146A (ja) 2021-12-16
JP2021535146A5 JP2021535146A5 (OSRAM) 2023-02-07
JP7525903B2 true JP7525903B2 (ja) 2024-07-31

Family

ID=69230180

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510759A Active JP7525903B2 (ja) 2018-08-31 2019-08-30 Ｃｘｃｒ４阻害剤の組成物ならびに調製および使用の方法
JP2024111620A Pending JP2024138443A (ja) 2018-08-31 2024-07-11 Ｃｘｃｒ４阻害剤の組成物ならびに調製および使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024111620A Pending JP2024138443A (ja) 2018-08-31 2024-07-11 Ｃｘｃｒ４阻害剤の組成物ならびに調製および使用の方法

Country Status (12)

Country Link
US (5) US10548889B1 (OSRAM)
EP (1) EP3843720A4 (OSRAM)
JP (2) JP7525903B2 (OSRAM)
KR (2) KR20260019556A (OSRAM)
AU (1) AU2019328530B2 (OSRAM)
BR (1) BR112021003467A2 (OSRAM)
CA (1) CA3110735A1 (OSRAM)
EA (1) EA202190377A9 (OSRAM)
IL (1) IL281082A (OSRAM)
MX (1) MX2021002180A (OSRAM)
SG (1) SG11202101814RA (OSRAM)
WO (1) WO2020047410A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
HUE060517T2 (hu) 2015-12-22 2023-03-28 X4 Pharmaceuticals Inc Immunhiányos betegség kezelésére szolgáló eljárások
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
WO2017223229A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
US10548889B1 (en) * 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US11878009B2 (en) * 2019-09-10 2024-01-23 Great Novel Therapeutics Biotech & Medicals Corporation Anticancer combination of chidamide and celecoxib salts
JP2023517956A (ja) * 2020-03-10 2023-04-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 好中球減少症を処置する方法
MX2024004165A (es) * 2021-10-07 2024-05-10 X4 Pharmaceuticals Inc Sintesis de mavorixafor e intermediarios del mismo.
EP4444304A4 (en) * 2021-12-09 2025-12-17 X4 Pharmaceuticals Inc METHOD FOR THE TREATMENT OF PRIMARY IMMUNE DISCOMFORT
WO2023240259A1 (en) * 2022-06-10 2023-12-14 X4 Pharmaceuticals, Inc. Treatments for conditions involving increased il-6 levels
WO2024216075A1 (en) * 2023-04-13 2024-10-17 X4 Pharmaceuticals, Inc. Synthesis of mavorixafor and intermediates thereof
WO2024216114A1 (en) * 2023-04-13 2024-10-17 X4 Pharmaceuticals, Inc. Synthesis of mavorixafor and intermediates thereof
WO2024216095A1 (en) * 2023-04-13 2024-10-17 X4 Pharmaceuticals, Inc. Synthesis of mavorixafor and intermediates thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005518397A (ja) 2001-12-21 2005-06-23 アノーメド インコーポレイテッド 高い有効性を有するケモカインレセプタ結合複素環式化合物
JP2007502864A (ja) 2003-05-23 2007-02-15 アノーメッド インコーポレイティド 有効性を高めたケモカインレセプタ結合複素環化合物
JP2007529526A (ja) 2004-03-15 2007-10-25 アノーメッド インコーポレイティド Ｃｘｃｒ４アンタゴニストの合成プロセス
US9267934B2 (en) 2010-10-26 2016-02-23 University Of South Alabama Methods and compositions for ameliorating pancreatic cancer
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4933447A (en) 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9200245D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
US5235056A (en) 1992-04-22 1993-08-10 Ciba-Geigy Corporation Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
AU6887996A (en) 1995-09-01 1997-04-01 Washington University School Of Medicine Method of reducing neurotoxic injury with zinc chelators
NZ331875A (en) 1996-03-22 2000-01-28 Du Pont Pharm Co Asymmetric synthesis of R-alpha-propyl-piperonyl amine and its analogs
ATE222104T1 (de) 1997-06-02 2002-08-15 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
CA2296314A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6525042B1 (en) 1997-09-30 2003-02-25 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
GB9726229D0 (en) 1997-12-12 1998-02-11 Zeneca Ltd Resolution of chiral amines
US6172061B1 (en) 1997-12-19 2001-01-09 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
US6607799B1 (en) 1998-10-15 2003-08-19 3M Innovative Properties Company Surgical dressing with delivery system and method of manufacture
US6635278B1 (en) 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
AP1654A (en) 1999-03-24 2006-09-01 Anormed Inc Chemokine receptor binding heterocyclic compounds.
US6245799B1 (en) 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
MXPA03002325A (es) 2000-09-15 2003-06-24 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina.
US6864265B2 (en) 2000-09-15 2005-03-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
DK1317451T3 (da) 2000-09-15 2006-12-18 Anormed Inc Kemokinreceptorbindende heterocykliske forbindelser
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
US7071189B2 (en) 2001-04-27 2006-07-04 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
JP5137288B2 (ja) 2001-07-31 2013-02-06 アノーメッド インコーポレイティド 前駆／幹細胞を動員する方法
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US20030055876A1 (en) * 2001-08-29 2003-03-20 Aravinda Korala Printing web content from self-service kiosks
PL372705A1 (en) 2001-09-12 2005-07-25 Anormed Inc. Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7491544B2 (en) 2002-05-20 2009-02-17 New York University Chiral piperidine and quinucledine ligands
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
WO2004052862A1 (ja) 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
JP2006523237A (ja) 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ， インコーポレイテッド Ｐｉ−３キナーゼインヒビタープロドラッグ
CA2520259A1 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
CA2517077C (en) 2003-04-22 2013-03-12 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7501518B2 (en) 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
US7425553B2 (en) 2003-05-30 2008-09-16 Gemin X Pharmaceuticals Canada Inc. Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
CA2531069A1 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
US7459457B2 (en) 2004-04-13 2008-12-02 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
DE102004021716A1 (de) 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
EP1761540B1 (en) 2004-05-13 2016-09-28 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
CA2575560A1 (en) 2004-08-02 2006-02-23 Smithkline Beecham Corporation Chemical compounds
AR050522A1 (es) 2004-08-16 2006-11-01 Smithkline Beecham Corp Derivados de bencimidazol como moduladores de la actividad de los receptores de quimioquina; composiciones farmaceuticas que los contienen; metodos para su preparacion y su uso en la fabricacion de medicamentos para el tratamiento contra infecciones por hiv
MX2007002679A (es) 2004-09-02 2007-05-16 Smithkline Beecham Corp Compuestos quimicos.
WO2006036816A2 (en) 2004-09-24 2006-04-06 Smithkline Beecham Corporation Chemical compounds
TW200619206A (en) 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
JP4801096B2 (ja) 2005-01-19 2011-10-26 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
EP1853604A4 (en) 2005-03-04 2010-02-24 Smithkline Beecham Corp CHEMICAL COMPOUNDS
EP2757099B1 (en) 2005-05-12 2017-08-23 AbbVie Bahamas Limited Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
ATE476529T1 (de) 2005-07-08 2010-08-15 Siemens Healthcare Diagnostics Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie
EP1904501A2 (en) 2005-07-11 2008-04-02 Smithkline Beecham Corporation Chemical compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
EP1910426B1 (en) 2005-08-02 2018-01-03 Ineos Sales (UK) Limited Diene polymerisation
CA2619828A1 (en) 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
WO2007027999A2 (en) 2005-08-31 2007-03-08 Smithkline Beecham Corporation Chemical compounds
AU2006302179C1 (en) 2005-10-07 2013-06-20 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
EP1961744B1 (en) 2005-11-18 2013-04-17 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
CA2629037A1 (en) 2005-11-30 2007-06-07 Schering Corporation Compositions comprising a combination of ccr5 and cxcr4 antagonists
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR059197A1 (es) 2006-01-25 2008-03-19 Smithkline Beecham Corp Derivados de indazolo piridina para el tratamiento de hiv
WO2007087548A2 (en) 2006-01-25 2007-08-02 Smithkline Beecham Corporation Chemical compounds
GB0605786D0 (en) 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
RU2439074C2 (ru) 2006-04-26 2012-01-10 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К)
WO2007130373A2 (en) 2006-05-01 2007-11-15 Capricorn Pharma, Inc. Novel triptan formulations and methods for making them
WO2007144720A2 (en) 2006-06-12 2007-12-21 Pfizer Products Inc. Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
US8486941B2 (en) 2007-03-12 2013-07-16 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
PT2155747E (pt) 2007-05-10 2012-12-19 Ge Healthcare Ltd Imidazol(1,2-a)piridinas e compostos relacionados com actividade nos receptores de canabinóides cb2
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
WO2009026251A1 (en) 2007-08-17 2009-02-26 The General Hospital Corporation Detecting ions and measuring ion concentrations
US9101628B2 (en) 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
TWI444382B (zh) 2008-03-11 2014-07-11 Incyte Corp 作為ｊａｋ抑制劑之氮雜環丁烷及環丁烷衍生物
WO2009117710A2 (en) 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treating inflammation
BRPI0909375A2 (pt) 2008-03-28 2015-08-04 Altiris Therapeutics Moduladores de receptores de quimiocinas
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP2010016628A (ja) 2008-07-03 2010-01-21 Canon Inc 画像処理装置及び画像処理方法
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
US9119790B2 (en) 2009-09-28 2015-09-01 Zenbury International Limited Pharmaceutical composition
US20110290821A1 (en) 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
CA2706292A1 (en) 2010-05-28 2011-11-28 Pharmascience Inc. A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
WO2012047339A2 (en) 2010-06-28 2012-04-12 The General Hospital Corporation Anti-cxcr4 as a sensitizer to cancer therapeutics
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
AU2011336397B2 (en) 2010-12-03 2016-12-15 Emory University Chemokine CXCR4 receptor modulators and uses related thereto
US8435993B2 (en) 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9314450B2 (en) 2011-01-11 2016-04-19 Dimerix Bioscience Pty Ltd. Combination therapy
US20150030561A1 (en) 2011-05-16 2015-01-29 Genzyme Corp. Use of CXCR4 Antagonists
AR087364A1 (es) 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
AU2013207825A1 (en) 2012-01-12 2014-08-28 Gilead Sciences, Inc. Pharmaceutical compositions and methods for their preparation
US20150301058A1 (en) 2012-11-26 2015-10-22 Caris Science, Inc. Biomarker compositions and methods
US10064826B2 (en) 2013-03-15 2018-09-04 Navinta, Llc Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
BR112015030518A2 (pt) 2013-06-05 2017-08-29 Salk Inst For Biological Studi Composição farmacêutica, uso de um ou mais agonistas do receptor da vitamina d (vdr), e, método para a redução da atividade biológica do ligante 12 do motivo c-x-c (cxcl12)
EP3030322A2 (en) 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
CA3206628A1 (en) 2013-09-12 2015-03-19 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating waldenstrom's macroglobulinemia
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
US10280183B2 (en) 2014-03-18 2019-05-07 The Research Foundation For The State University Of New York Therapeutic agent for treating tumors
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US10450293B2 (en) 2014-05-16 2019-10-22 Emory University Chemokine CXCR4 and CCR5 receptor modulators and uses related thereto
EP3157921A1 (en) 2014-06-23 2017-04-26 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
EP3552615B8 (en) 2014-07-16 2022-03-02 Transgene Oncolytic virus for expression of immune checkpoint modulators
US20170340693A1 (en) 2014-12-12 2017-11-30 Commonwealth Scientific And Industrial Research Organisation Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
MX2017015811A (es) 2015-06-12 2018-04-10 Squibb Bristol Myers Co Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10379661B2 (en) 2015-09-25 2019-08-13 Samsung Electronics Co., Ltd. Coordinate measuring apparatus and coordinate measuring system having the same
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
HUE060517T2 (hu) 2015-12-22 2023-03-28 X4 Pharmaceuticals Inc Immunhiányos betegség kezelésére szolgáló eljárások
EP3405203A4 (en) 2016-01-22 2019-07-24 X4 Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
US11353459B2 (en) 2016-04-14 2022-06-07 Creatv Microtech, Inc. Methods of using PD-L1 expression in treatment decisions for cancer therapy
WO2017189999A1 (en) 2016-04-29 2017-11-02 Dana-Farber Cancer Institute, Inc. Hck as a therapeutic target in myd88 mutated diseases
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
WO2017223229A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
JP2020525427A (ja) 2017-06-21 2020-08-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置するための方法
CA3080821A1 (en) 2017-11-07 2019-05-16 X4 Pharmaceuticals, Inc. Cancer biomarkers and methods of use thereof
EP3727381A4 (en) 2017-12-19 2022-01-19 X4 Pharmaceuticals, Inc. Acyclic cxcr4 inhibitors and uses thereof
WO2019200223A1 (en) 2018-04-13 2019-10-17 X4 Pharmaceuticals, Inc. Cancer serum biomarkers and methods of use thereof
US10548889B1 (en) * 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN210928127U (zh) 2019-10-23 2020-07-03 奥特斯(中国)有限公司 部件承载件

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005518397A (ja) 2001-12-21 2005-06-23 アノーメド インコーポレイテッド 高い有効性を有するケモカインレセプタ結合複素環式化合物
JP2007502864A (ja) 2003-05-23 2007-02-15 アノーメッド インコーポレイティド 有効性を高めたケモカインレセプタ結合複素環化合物
JP2007529526A (ja) 2004-03-15 2007-10-25 アノーメッド インコーポレイティド Ｃｘｃｒ４アンタゴニストの合成プロセス
US9267934B2 (en) 2010-10-26 2016-02-23 University Of South Alabama Methods and compositions for ameliorating pancreatic cancer
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
US10548889B1 (en) 2020-02-04
AU2019328530B2 (en) 2025-02-27
US12115156B2 (en) 2024-10-15
MX2021002180A (es) 2021-09-14
US20220008410A1 (en) 2022-01-13
EP3843720A4 (en) 2022-07-27
US20200253953A1 (en) 2020-08-13
KR20210095118A (ko) 2021-07-30
WO2020047410A1 (en) 2020-03-05
KR102908092B1 (ko) 2026-01-07
US20250228843A1 (en) 2025-07-17
US20240058322A1 (en) 2024-02-22
KR20260019556A (ko) 2026-02-10
AU2019328530A1 (en) 2021-04-01
EA202190377A1 (ru) 2021-07-22
CN112839649A (zh) 2021-05-25
IL281082A (en) 2021-04-29
EA202190377A9 (ru) 2021-08-09
JP2024138443A (ja) 2024-10-08
CA3110735A1 (en) 2020-03-05
EP3843720A1 (en) 2021-07-07
BR112021003467A2 (pt) 2021-05-18
US11672793B2 (en) 2023-06-13
SG11202101814RA (en) 2021-03-30
JP2021535146A (ja) 2021-12-16
US11045461B2 (en) 2021-06-29

Similar Documents

Publication Publication Date Title
US12115156B2 (en) Compositions of CXCR4 inhibitors and methods of preparation and use
US20240254120A1 (en) Ep4 inhibitors and synthesis thereof
JP2023538906A (ja) ネクチン－４に特異的な二環コンジュゲート及びその使用
JP2023553866A (ja) Ｔｅａｄ阻害剤、及びその使用
US12295962B2 (en) Polymorphic compounds and uses thereof
US11878958B2 (en) MEK inhibitors and uses thereof
WO2023173053A1 (en) Mek inhibitors and uses thereof
WO2023173057A1 (en) Mek inhibitors and uses thereof
TW202329962A (zh) 治療癌症之方法
CN112839649B (en) CXCR4 inhibitor compositions and methods of making and using the same
TW201343169A (zh) 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法
EA046788B1 (ru) Композиции ингибиторов cxcr4, способы получения и применения
CN114206869A (zh) Cxcr4抑制剂和其用途
US20220017487A1 (en) Deuterated compounds and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240611

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240711

R150 Certificate of patent or registration of utility model

Ref document number: 7525903

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150